Key stats
About iShares Trust iShares Neuroscience and Healthcare ETF
Expense ratio
0.47%
Home page
Inception date
Aug 24, 2022
IBRN is the first ETF to have a global pure-play bet on neurosciences that specifically focuses on research, development, or manufacturing of neurology biopharmaceuticals or neurological devices. These are typically associated with the treatment of neurological disorders. The index includes companies in the sub-industries classified as either/or Neurology Biopharmaceuticals and Neurology Devices by the FactSet RBICS. Eligible companies must have 50% of their annual revenues or, for pre-revenue companies, their primary business must be under listed sub-industries. Companies whose business description, trade names, or supply chain relationships indicate involvement with psychedelics or cannabis, based on an analysis using FactSet keyword data, are explicitly excluded. Eligible equities include large- to small-cap companies that meet liquidity and tradability criteria. The market cap-weighted index is reviewed and reconstituted semi-annually starting March and rebalanced quarterly.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.